In rare diseases, the eligible population may be a few hundred people scattered across a dozen countries, and many are already searching online for options long before they reach a study site. This session shows how sponsors can reach those patients directly, in their own language, and connect them to active sites ready to screen.
Adnexi will walk through its innovative Direct-to-Patient Enrollment Accelerator: compliant digital campaigns across 20 countries, IRB/EC-approved pre-screeners, and a referral portal that gives sites and sponsors visibility from first contact through randomization. Adnexi will then turn to it’s exhaustive global PAG platform, which identifies, profiles and engages patient advocacy groups in a specific disease state to augment enrollment.
Attendees will leave with a deep understanding of the latest innovations in patient enrollment for rare diseases.
What is really stopping us today: Lack of internal training, Limited digital integration, Scalability pressures, Other operational or regulatory barriers. What next practical steps can we take to overcome these hurdles?
- How to plan and allocate resources effectively across the full study lifecycle (from manufacturing to release and distribution)
- How to prepare for audits and inspections proactively incorporating audit readiness into daily workflows to avoid last minute firefighting
- The value of leveraging external partners and CDMOs effectively to improve quality oversight with limited internal teams
Moderator: Paul Hingst, Supply Chain Consultant, Crinetics Pharmaceuticals
Panelist 1:Ted Chun, VP Regulatory, Quality & Clinical, Prometheus Therapeutics
Panelist 2: Pooja Gandhi, Director, Clinical Quality Assurance, Grail
Prize Draw taking place in exhibition hall at 14:15
Join us for a chance to win one of our prizes, including Apple products
Prize Draw taking place in exhibition hall at 14:15
Join us for a chance to win one of our prizes, including Apple products
